Abstracts tagged "population studies"

Abstract Number: 1722 • ACR Convergence 2025
Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care
Shivani Garg¹, Benoit Blanchet², Yann Nguyen³, Fauzia Hollnagel⁴, Ada Clarke⁵, Michelle Petri⁶, Murray Urowitz⁷, John Hanly⁸, Caroline Gordon⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Jorge Sanchez-Guerrero¹², Ann Clarke¹³, Sasha Bernatsky¹⁴, Daniel Wallace¹⁵, David A. Isenberg¹⁶, Anisur Rahman¹⁶, Joan Merrill¹⁷, Paul Fortin¹⁸, Dafna D. Gladman¹⁹, Ian Bruce²⁰, Ellen Ginzler²¹, Mary Anne Dooley²², Rosalind Ramsey-Goldman²³, Susan Manzi²⁴, Andreas Jönsen²⁵, Graciela Alarcón²⁶, Ronald van Vollenhoven²⁷, Cynthia Aranow²⁸, Murat Inanc²⁹, Meghan mackay³⁰, Guillermo Ruiz-Irastorza³¹, S. Sam Lim³², Murat Inac³³, Kenneth Kalunian³⁴, Søren Jacobsen³⁵, Christine Peschken¹¹, Diane Kamen³⁶, Anca Askanase³⁷, Jill Buyon³⁸, Julie Chezel⁵, Alicja Puszkiel³⁹ and Nathalie Costedoat-Chalumeau⁴⁰, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France, ³Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ⁴University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ⁵Cochin Hospital, Paris, France, ⁶Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Toronto, Toronto, ON, Canada, ⁸Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁹Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ¹⁰Hanyang University Medical Center, Seoul, South Korea, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Mount Sinai Hospital and University Health Network, Toronto, Canada, ¹³Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁵Cedars Sinai Medical Center, Studio City, CA, ¹⁶University College London, London, United Kingdom, ¹⁷Oklahoma Medical Research Foundation, Oklahoma, ¹⁸Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ²⁰Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, ²¹SUNY Downstate Health Sciences University, New York, NY, ²²UNC physician network, Chapel Hill, NC, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²⁵Department of Clinical Sciences, Lund University, Lund, Sweden, ²⁶The University of Alabama at Birmingham, Oakland, CA, ²⁷Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ²⁸Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²⁹Istanbul University, Istanbul, Turkey, ³⁰Feinstein Institutes for Medical Research, Manhasset, NY, ³¹Biobizkaia Health Research Institute, Barakaldo, Spain, ³²Emory University School of Medicine, Atlanta, GA, ³³Istanbul University, Istanbul, ³⁴UC San Diego, La Jolla, CA, ³⁵Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁶Medical University of South Carolina, Johns Island, SC, ³⁷Columbia University Medical Center, New York, NY, ³⁸NYU Grossman School of Medicine, New York, NY, ³⁹Cochin Hospital, Paris, ⁴⁰Inserm DR Paris ⁵, Paris, France
Background/Purpose: Current guidelines recommend using hydroxychloroquine (HCQ) dose ≤5.0 mg/kg for managing SLE. However, 6-fold higher SLE flares, including those requiring hospitalizations, are noted with…
Abstract Number: 0030 • ACR Convergence 2025
Immune-related Diagnoses Associated with NOD2 Variants in Human Subjects: A Phenome-wide Association Study
John Davis¹, Elizabeth Atkinson¹, Vanessa Kronzer¹, Cynthia Crowson², Afsaneh Alavi³, John Damianos¹, Loftus Edward¹, Joseph Murray¹, Ann Moyer¹ and Filippo Pinto e Vairo¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Stewartvillle, MN, ³Department of Dermatology, Mayo Clinic, Rochester, MN
Background/Purpose: The nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene is associated with risk for several inflammatory diseases, including Crohn disease, Blau syndrome, and Yao syndrome…
Abstract Number: 1638 • ACR Convergence 2025
Comparison and Assessment of the All of Us Dataset for Epidemiologic Studies of Systemic Lupus Erythematosus (SLE) Among African American Women
Katherine Singleton¹, Sarah Smith², Charmayne Dunlop-Thomas³, L. Quinnette King², Lori Ann Ueberroth⁴, Edith Williams⁵, S. Sam Lim⁶, Bethany Wolf², Diane Kamen⁷ and Paula Ramos⁶, ¹Emory University School of Medicine, Atlants, GA, ²Medical University of South Carolina, Charleston, SC, ³Emory University, Atlanta, GA, ⁴Medical University of South Carolina, Charleston, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Medical University of South Carolina, Johns Island, SC
Background/Purpose: Health disparities in SLE are well established, with African American women being disproportionately impacted. Despite the known associations between sociodemographic and genetic factors with…
Abstract Number: 1636 • ACR Convergence 2025
The Impact of Arthritis on Self-Management Activities of West Virginia Adults with Type 2 Diabetes During the COVID-19 Pandemic
Dina Maruca¹, Teresa Brady², Gerald Hobbs, Jr.¹ and Ranjita Misra¹, ¹West Virginia University, Morgantown, WV, ²Clarity Consulting and Communications, Atlanta, GA
Background/Purpose: One-third of adults with Type 2 diabetes (T2D) also have arthritis. West Virginia (WV), the 3rd most rural US state, has the highest prevalence…
Abstract Number: 1471 • ACR Convergence 2025
Prevalence and Clinical Outcomes of Hemophagocytic Lymphohistiocytosis in Systemic Lupus Erythematosus: A Multi-Institutional Cohort Study
Amir Daneshvar¹, Julia Wajsberg¹, Chelsea Guan¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker², Meghan Gump¹ and Omer Pamuk³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement. A rare but life-threatening hyper-inflammatory hematological complication of SLE is hemophagocytic lymphohistiocytosis…
Abstract Number: 1148 • ACR Convergence 2025
Interstitial Lung Disease in MCTD: A Retrospective Cohort Study at a Large Tertiary Medical Center
Alana Haussmann¹ and Elizabeth Volkmann², ¹University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare autoimmune condition defined by the presence of anti-U1-ribonucleoprotein (RNP) antibodies and clinical features of at least…
Abstract Number: 1081 • ACR Convergence 2025
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
Ramsha Riaz¹, Lifang Zhang², Andrea Berger², Hema Srinivasan², Lisa Schroeder³ and Jonida Cote⁴, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Health System, Danville, PA, ³Geisinger, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
Abstract Number: 2659 • ACR Convergence 2025
Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Systemic Autoimmune Rheumatic Diseases in Patients with Type 2 Diabetes: A Population-Based Target Trial Emulation
Jamie Chieh Lo¹, Karen H. Costenbader² and Kevin Sheng-Kai Ma³, ¹National Taiwan University Hospital, Keelung, Taipei, Taiwan (Republic of China), ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA
Background/Purpose: Treatment with dipeptidyl peptidase-4 inhibitors (DPP4i) have been shown to reduce the risk of systemic autoimmune rheumatic diseases (SARD) in patients with type 2…
Abstract Number: 1031 • ACR Convergence 2025
Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Satani Sharkas¹, Dina Murad² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Tufts Medical Center, Boston, MA, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Rheumatoid arthritis (RA) is a growing public health concern in the United States, with increasing prevalence and disease burden over recent decades. This study…
Abstract Number: 2590 • ACR Convergence 2025
Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
Sharan Rai¹, Natalie McCormick², Xochitl Morgan³, Matthew Nayor⁴, Robert Terkeltaub⁵, Dylan Dodd⁶, Lama Nazzal⁷, Huilin Li⁷, Gary Curhan⁸, Curtis Huttenhower³ and Hyon K. Choi⁹, ¹Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, ⁴Boston University, Boston, ⁵Retired, San Diego, CA, ⁶Stanford University, Palo Alto, CA, ⁷NYU Langone, New York, NY, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Approximately 21% of US adults have hyperuricemia, the causal precursor for gout. Human cells do not degrade urate (due to uricase gene inactivation). However,…
Abstract Number: 1018 • ACR Convergence 2025
Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
José Gomez-Puerta¹, Cristian Tebe², Maria Grau³, Beatriz Frade Sosa⁴, Juan Camilo Sarmiento-Monroy⁵, Cristina Carbonell-Abella⁶, Daniel Martinez-Laguna⁷, Patricia Corzo⁸, Raimon Sanmartí⁹ and J. Antonio Aviña-Zubieta¹⁰, ¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Instituto de Investigación Germans Trias i Pujol, Badalona, Spain, ³University of Barcelona, Barcelona, Spain, ⁴Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁵Hospital Clínic Barcelona, Barcelona, Spain, ⁶Medicina Familiar y Comunitaria, Centro de Salud Vía Roma, Barcelona, Spain, ⁷Grup de recerca en malalties prevalents de l'Aparell locomotor en Atenció Primaria (GREMPAL), ICS, Barcelona, Spain, ⁸Rheumatology Department, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁰University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: The differences in lupus-related mortality reported in population studies are partly explained by racial disparities and access to healthcare. However, population-based data from universal…
Abstract Number: 2571 • ACR Convergence 2025
Rare Clinically Significant Methotrexate Toxicity Despite Frequent Laboratory Abnormalities: A Population-Based Study of Methotrexate Monitoring
Griffin Reed¹, Jeffrey Yang¹, Georges El Hasbani¹, Cynthia Crowson², Hannah Langenfeld¹, Jeffrey Sparks³, Bryant England⁴, gabriela Schmajuk⁵, Kaleb Michaud⁴, John Davis¹ and Vanessa Kronzer¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Stewartvillle, MN, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Methotrexate laboratory monitoring is highly resource intensive, and recent evidence questions whether the true toxicity of methotrexate has been over-estimated. Therefore, we aimed to…
Abstract Number: 0675 • ACR Convergence 2025
Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.
Shiri Keret¹, Shlomit Yaari², gleb Slobodin³ and doron Rimar³, ¹Bnai Zion Medical Center, Atlit, Israel, ²Maccabi Healthcare Services, HaMered ²⁷, Tel Aviv, ⁶⁸¹²⁵, Israel., Tel Aviv, Israel, ³Bnai Zion Medical Center Faculty of Medicine, Technion Israel institute of technology, Haifa, Israel
Background/Purpose: Elevated neutrophil-to-lymphocyte ratio (NLR) in systemic sclerosis (SSc) has been demonstrated to predict worsening skin and lung involvement, and a cutoff of 2.95 was…
Abstract Number: 2400 • ACR Convergence 2025
Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing
Henrik Zachar Langkilde¹, Jesper Davidsen², Stefan Harders³, Stefan Luef⁴, Susan Kay⁵, Tine Lottenburger⁶, Stavros Chrysidis⁷, Karen Schreiber⁸, Elisabet Svenungsson⁹, Sille Fløjborg¹⁰, Robin Christensen¹¹ and Anne Voss¹², ¹Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense, Denmark, ²South Danish Center for Interstitial Lung Diseases (SCILS) and Pulmo-Rheuma Frontline Center (PURE), Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark, Odense, Syddanmark, Denmark, ³Research Unit of Department of Radiology, University of Southern Denmark, Odense University Hospital, Denmark., Odense, Syddanmark, Denmark, ⁴Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark, Odense, Syddanmark, Denmark, ⁵Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, ⁶Department of Rheumatology, Vejle Hospital, Vejle, Denmark, Vejle, Syddanmark, Denmark, ⁷Department of Rheumatology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark, Esbjerg, Syddanmark, Denmark, ⁸Danish Center for Expertise in Rheumatology (CeViG), Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, Soenderborg, Syddanmark, Denmark, ⁹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ¹⁰Systemic Lupus Erythematosus Patient Research Partner, Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Hovedstaden, Denmark, ¹²Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense C, Syddanmark, Denmark
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that potentially affects any organ. Pulmonary diseases (PD) are common in SLE and cover several different…
Abstract Number: 0603 • ACR Convergence 2025
Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Amir Daneshvar¹, Areeb Tiwana², Dana Nachawati¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker³, Meghan Gump¹ and Omer Pamuk⁴, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²Canton Medical Education Foundation, Canton, OH, ³University hospitals Cleveland medical center, Highland Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with widespread clinical manifestations. Neuropsychiatric SLE (NPSLE), a complex and poorly understood subset of SLE,…

1
2
3
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].